

### ACCP Mentors

<u>First Name</u>	<u>Last Name</u>	<u>Degree(s)</u>	<u>Affiliation</u>	<u>Country</u>	<u>Specialty Area</u>	<u>Group to Mentor</u>
Vikram	Arya	PhD	Government/Regulatory	US	Dr. Vikram Arya earned his Ph.D. in Pharmaceutics from the University of Florida. He has published articles on drug-drug interactions and impact of transporter modulation on drug disposition and has presented at various conferences. He is a Fellow of the American College of Clinical Pharmacology (ACCP) and currently serves as President-Elect of ACCP. He holds an Adjunct Clinical Professor appointment in the Department of Pharmacy Practice at Mercer University, Atlanta, GA, Adjunct Assistant Professor appointment in the Department of Pharmaceutical Sciences at the University of Tennessee, Adjunct Associate Professor appointment in the Department of Pharmaceutics, University of Florida, and Adjunct Professor appointment in the Department of Pharmacotherapy in the University of North Texas System College of Pharmacy. He serves on the Editorial Board of the Journal of Clinical Pharmacology (JCP) and International Journal of Clinical Pharmacology and Therapeutics (IJCP).	Young Professionals Industry/Regulatory Track
Kacey	Anderson	PhD	Industry	US	Dr. Anderson is a clinical pharmacologist working in the pharmaceutical industry. She has comprehensive clinical pharmacology experience from Phase 1 to Phase 3 and has been the clinical pharmacology lead on several project teams for inflammation small molecules. She has experience in authoring multiple regulatory submissions, included IND/CTA submissions and NDA/MAA/PMDA submissions.	Students & Trainees (undergrad, graduate, post-doc); Young Professionals Industry/Regulatory Track
Joe	Bertino	PharmD	Consulting	US	Dr Bertino has experience in both Pediatric and Adult Clinical Pharmacology, in patient care, research and teaching. He is currently the Editor-in-Chief of the Journal of Clinical Pharmacology. His expertise included drug metabolism and PK/PD application for drugs.	Students & Trainees, Academic junior faculty
Christine	Brandquist	PharmD	Industry	US	Dr. Brandquist a clinical pharmacokineticist with a focus on pharmacokinetic and pharmacodynamic assessments in Phase 1 clinical trials. She is involved in study design development and submission-ready protocol writing, data analysis, and report writing. The types of Phase 1 studies that she typically works on are First-in-Human Single and Multiple Ascending Doses, Bioavailability, Bioequivalence, Food Effect, Drug-Drug Interactions, Renal Impairment, Hepatic Impairment, and Gender/Ethnicity studies. In addition, she has experience in population pharmacokinetics/pharmacometrics. Dr. Brandquist is a long-time Member of ACCP and has served in many roles, including as the Chair of the Membership Committee, and has mentored many young colleagues.	Students & Trainees (undergrad, graduate, post-doc); Young Professionals Industry/Regulatory Track
Adam	Cohen	MD, PhD	Academia	EU	Adam Cohen is a physician clinical pharmacologist with a clinical background in nephrology and emeritus professor in the Leiden University Medical Hospital. Adam founded CHDR in 1987 and led it to its current position as one of the largest not for profit experimental units in the world.	All levels
Lawrence	Cohen	PharmD	Academia	US	Dr. Cohen's research and scholarly interests include development of new/novel treatments for psychiatric disorders, pharmacokinetics and pharmacodynamics of psychotropic medications, geriatric psychopharmacology, pharmacoconomics and health outcomes, pharmacoepidemiology, health disparities and emergency preparedness (specifically, access and affordability of healthcare during times of crisis).	Students & Trainees, Academic junior faculty
Jonathan	Constance	PhD	Academia	us	Dr. Constance is a board-accredited clinical pharmacologist with advanced training in molecular biology. His primary focus is on the pharmacokinetic and pharmacodynamic consequences of drug interactions affecting children with cancer. Drug interactions are common among patients with cancer, but interpreting the risks (or benefits) to safety and efficacy require interpretation within genetic, developmental, and pathophysiologic contexts. His research seeks to identify opportunities to optimize drug therapy and improve health outcomes. Dr. Constance is a previous ACCP Student Abstract Award Winner and the winner of the 2015 Wayne A Colburn Award. He currently serves as the Chair of the ACCP Working Group on Early-stage Professionals.*	Students & Trainees (undergrad, graduate, post-doc); Young Professionals Academic Track
Matthew	Dufek	PhD	Industry	US	Dr. Dufek is Director of Clinical pharmacology at Abbvie in the department of clinical pharmacology and pharmacometrics (since 2013). He is the lead clinical pharmacology representative on the global development teams within the General Medicine Therapeutic Area. Some of the compounds he currently supports are in the therapeutic areas of cystic fibrosis, oncology, anti-infective (HIV and HCV), men's & women's health (endometriosis and fibroids), renal disease, pediatric and mature products. The majority of his responsibilities are leading the development of and strategic planning of clinical development plans for the execution of Phase 1-3 clinical studies within these project teams and review of proposals with executive management and governance committees. Other responsibilities have included, serving as clinical pharmacology team lead and steering committee member for external collaborations between AbbVie and other pharmaceutical development companies (US and Global) and external asset review and due diligences.	Students & Trainees (PhD and post-doc); Young Professionals Industry Track
Mike	Fossler	PharmD, PhD, FCP	Industry	US	Michael J. Fossler is Vice-President, Clinical Development and Quantitative Sciences, at Trevena, Inc. From 1995 to 2000, Dr. Fossler was employed by the FDA as a clinical pharmacology reviewer in the Division of Metabolic and Endocrine Drug Products. In 1998, he was promoted to Senior Reviewer, and joined the Pharmacometrics group at FDA, where he was responsible for reviewing and performing population PK/PD analyses. He left the Agency in 2000 and joined the Clinical Pharmacokinetics Group at DuPont Pharmaceuticals, where he had major responsibility for PK/PD analyses in the cardiovascular and anti-inflammatory areas. In November, 2001, he joined GlaxoSmithKline, where he continued to work in the cardiovascular area, and eventually headed a group of nine pharmacometrics scientists. He left GSK in 2015 to assume his present role at Trevena, Inc., where he heads up clinical pharmacology, clinical operations, biostatistics, programming and data management. He received a Pharm. D. (1992) and Ph. D. (1995) degrees from the University of Maryland. Dr. Fossler is a Fellow of the American Foundation for Pharmaceutical Education, a Fellow of the American College of Clinical Pharmacology, a past President of the College and is an Honorary Regent. He holds adjunct faculty appointments at the University of Maryland School of Pharmacy, Mercer University, and the University of North Texas, and is on the faculty of the University of California's American Course on Drug Development and Regulatory Science.	Students & Trainees (PhD and post-doc); Young Professionals Industry Track

<u>First Name</u>	<u>Last Name</u>	<u>Degree(s)</u>	<u>Affiliation</u>	<u>Country</u>	<u>Specialty Area</u>	<u>Group to Mentor</u>
John	Foxworth	PharmD	Academia	US	Dr. Foxworth's research interests are in evidence-based medicine. Dr. Foxworth works with students and residents teaching research methodology, biostatistics and evidence-based medicine.	
Tushar	Garimella	PhD	Industry	US	Dr. Garimella is an industry professional with more than 12 years of experience in Clinical Pharmacology and Pharmacometrics in multiple therapeutic areas. Currently employed in Bristol-Myers Squibb as therapeutic area head for Clinical Pharmacology for Cardiovascular assets, Tushar has experience across all phases of drug development. Previous experience includes hepatitis C, neuroscience and CKD and extensive experience in model informed drug development and regulatory interactions with multiple agencies including FDA, EMA, PMDA, KFDA, CDE and TFDA.	Students & Trainees (undergrad, graduate, post-doc); Young Professionals Industry/Regulatory Track
Navin	Goyal	PhD	Industry	US	Dr. Goyal has 8 years of experience in Clinical Pharmacology and Pharmacometrics working in Industry (GlaxoSmithKline) in different therapy areas. He is happy to share experience and mentor trainees/young professionals of what skills they need to sharpen, what should they expect when joining the industry at entry level positions.	Students & Trainees; Young Professionals Industry/Regulatory
Oliver	Grundmann	PhD	Academia	US	Dr. Grundmann received a bachelor's degree in pharmacy and European pharmacist license from the University of Münster, Germany, in 2004 before beginning his graduate studies at the University of Florida. While continuing his Ph.D. in Pharmaceutical Sciences, he worked for the Forensic Science program after graduating with a master's degree in Forensic Toxicology and minor in Statistics. His research interests include the search for new treatment options from natural products for Central Nervous System and Gastrointestinal diseases such as anxiety and depressive disorders as well as irritable bowel syndrome and cancers of the gastrointestinal tract. He also is interested in the implementation and impact of national and international collaborations for curricular development in the health sciences with an emphasis on distance and online education. Dr. Grundmann serves as the Director and faculty advisor for the online Master of Science and graduate certificate programs in Pharmaceutical Chemistry and Clinical Toxicology at the College of Pharmacy.	Students & Trainees, Academic junior faculty
Neeraj	Gupta	PhD	Industry	US	Dr. Gupta is an expert in clinical pharmacology and pharmacometrics and has extensive experience as a drug developer in oncology drug development. He holds a PhD degree in Pharmaceutics from the Univ of Iowa with specialization in pharmacokinetic/pharmacodynamic sciences. He has held positions in the pharmaceutical industry at Abbott and Millennium/Takeda. Currently at Takeda, Dr. Gupta leads a group of PhD-level clinical pharmacologists responsible for representing the discipline on drug development program teams from translational research through late-stage clinical development. He directly serves as the Global Clinical Pharmacology Leader for two of Takeda Oncology's marketed products, the proteasome inhibitor ixazomib for multiple myeloma and the ALK inhibitor brigatinib for ALK+ Non-small cell lung cancer, where his superior scientific and strategic leadership have been central to the development of these drugs. Dr. Gupta has published over 40 peer-reviewed papers in prestigious journals and over 90 abstracts/conference presentations at national and international meetings serving the communities of clinical pharmacology, translational medicine, cancer research, oncology clinical medicine and drug development/regulatory science. He has served as an invited speaker/faculty member or session chair at multiple major national and international meetings and at the FDA on topics ranging from model-informed drug development, proarrhythmic risk assessment in drug development and clinical pharmacology/pharmacometrics in oncology drug development.	Students & Trainees, young professions (industry/regulatory) track
Silvia	Illamola	PhD	Academia	US	Dr. Illamola's research is focused on clinical pharmacology and pharmacometrics in neonatology and obstetrics. Of special interest is the influence of growth and development of often used medication on the pharmacokinetics and pharmacodynamics in newborns, children and infants. Additionally, her research includes the clinical pharmacology of medications during pregnancy and lactation.	Students & Trainees
Priyanka	Ingle	PhD	Consulting	US	Dr. Ingle-Jadhav is a Physician-Researcher specializing in Pharmaceutical Medicine, Clinical Pharmacology. One of the major areas of her research focuses on Complementary and Integrative Health Medicine involving both lab and clinical methods. She brings in expertise of diverse therapeutic areas like infectious diseases, immunology-autoimmune diseases, pathology, dermatology, diabetes and domains like Outcome research focusing on HRQOL studies. She received her medical degree and PhD in Pharmaceutical Medicine from State Health University, Mumbai, India and postdoctoral training at UF diabetes institute, University of Florida, Gainesville, Florida. She has published several peer reviewed research articles in reputed research journals, co-edited a book, authored chapters in books, presented at national and international conferences, won many awards and also contribute as associate editor to the Journal of Ayurveda and Integrative Medicine.	
Manoj	Jadhav	PhD	Industry	US	Dr. Jadhav is a PhD in Pharmaceutical Technology and a trained clinical pharmacologist. He has worked on both non-clinical and clinical drug development programs in infectious diseases and cardiovascular diseases both in India and USA. He has published over 25 research papers in peer reviewed journals and has worked at both industry and academia.	Students & Trainees, young professionals (industry/regulatory) track
Catherijne	Knibbe	PhD	Academia	EU		
Ahmed	Nader	PhD	Industry	US	Dr. Nader is the Assoc Director of Clinical Pharmacology Modeling & Simulation at GlaxoSmithKline	Students & Trainees, young professionals (industry/regulatory) track

<u>First Name</u>	<u>Last Name</u>	<u>Degree(s)</u>	<u>Affiliation</u>	<u>Country</u>	<u>Specialty Area</u>	<u>Group to Mentor</u>
Ahmed	Salem	PhD	Industry	US	Dr. Ahmed Salem is an associate director of Clinical Pharmacology and Pharmacometrics at AbbVie, North Chicago, USA, where he leads a group of clinical pharmacologists supporting the development of targeted anti-cancer agents. Dr. Salem is a pharmacist and holds a PhD in Clinical Pharmacology from University of Minnesota with minor in Biostatistics. Dr. Salem's research at University of Minnesota focused on pharmacometric analyses of anti-HIV and anti-MRSA agents. In the industry, Dr. Salem has supported the clinical development of small and large molecules in the oncology, virology and women's health therapeutic areas. Dr. Salem has contributed to the approval of several new and supplemental drug applications and marketing authorization applications. His most recent accomplishment was leading the clinical pharmacology strategy for the first-in-class BCL-2 inhibitor; venetoclax, contributing to its approval in the US and EU. Dr. Salem has published over 80 peer-reviewed publications including 33 original research articles. Dr. Salem serves on the STYP Committee of the American College of Clinical Pharmacology (ACCP) and on the publications committee of the International Society of Pharmacometrics (ISO-P). He is also a peer review for numerous clinical pharmacology journals and is a member of the Rho Chi pharmacy Phi Kappa Phi Honor societies.	Young Professionals/Industry Track
Mohamadi	Sarkar	M.Pharm., PhD, FCCP	Industry	US	Dr. Sarkar is a Fellow of Scientific Strategy at Altria Client Services LLC, and is an Affiliate Professor of Clinical Pharmacology at the Medical College of Virginia at VCU. He provides strategic direction towards developing the science and evidence for regulatory submissions for non-combustible tobacco products for Altria's tobacco operating companies. He has authored more than 100 scientific peer-reviewed publications and presentations at scientific meetings. Dr. Sarkar has also participated in multiple seminar presentations and authored a variety of scientific book chapters related to his areas of expertise.	All levels
Mohamadi	Shebley	PhD	Industry	US	Dr. Shebley received his PhD in Pharmacology from the Univ of Michigan, with focus on drug-drug interaction. He joined industry after graduation and worked across divisions of drug discovery and development, spanning DMPK, translational science, modeling and simulation, and clinical pharmacology and pharmacometrics. He is currently serving as Clinical Pharmacology Group Leader supporting PhD/PharmD clinical pharmacologists working across development projects ranging from FIH to commercialization in the Specialty therapeutic area (general medicine/infectious disease), with previous experience in oncology. He became a Fellow of Clinical Pharmacology in ACCP in 2019 and serves on the ACCP Membership Committee and ACCP 2022 Annual Meeting Programming Committee.	Students & Trainees, young professionals (industry/regulatory) track
Cynthia	Sung	PhD	Academia	Singapore	Dr. Sung is a Research Program Manager at the Health Sciences Authority. She has experience working for 2 regulatory agencies doing pre-market evaluation (FDA - IND and NDA evaluation for the Office of Clinical Pharmacology), and post-market safety surveillance and pharmacogenomics (Health Sciences Authority - Singapore). She also has 5 years of industry experience as Director of Pharmacokinetics (preclinical and clinical) at a mid-sized biotechnology company (Human Genome Sciences, Inc)	young professionals in the industry / regulatory track
John	van den Anker	MD, PhD	Academia	US	Johannes van den Anker, M.D., Ph.D., division chief of Clinical Pharmacology and vice chair of Pediatrics for Experimental Therapeutics at Children's National Health System. Dr. van den Anker specializes in pediatric pharmacology and therapeutics, and his work expanded and enhanced medical knowledge about the use of drugs in children and about the treatment of disease. He has also played an integral role in training the next generation of clinical pharmacists and pharmacologists.	All levels
Peter	Wiernik	MD	Non-profit	US	Dr. Wiernik is the founder of the Comprehensive Cancer Center at Our Lady of Mercy Medical Center in New York and served as Director until 2009. He is currently a member of the Board of Regents of the ACCP, and is also the immediate past Chair of the Eastern Division of the American Federation of Medical Research. At various times in his career, he was Professor of Medicine and Radiation Medicine at the University of Maryland School of Medicine, Albert Einstein College of Medicine, and New York Medical College. He was Editor of Medical Oncology from 1993 to 2014, as well as Consulting Editor for the Journal of Clinical Oncology from 2009 to 2015. Dr. Wiernik was President of the American Radium Society from 1993 to 1994 and received the society's Janeway Gold Medal in 1996. Dr. Wiernik is the author of more than 700 peer-reviewed papers and a dozen books, including Neoplastic Diseases of the Blood, which is currently in its 5th edition.	All levels

Updated 10/3/2021